Showing 2637 results
- Media Release /Phase III JUNIPERA study met its primary endpoint, with Cosentyx® (secukinumab) showing significantly longer time to flare (longer time to worsening of symptoms1) vs. placebo (P<.001) in pediatric…
- Media Release /Approval for moderate to severe pediatric patients six years and older is based on pivotal trial data showing Cosentyx demonstrated superior improvements of skin symptoms compared to placebo1…
- Media Release /If approved, Xolair® (omalizumab) will provide patients who have severe chronic rhinosinusitis with nasal polyps, not adequately controlled by intranasal corticosteroids, with the first anti-…
- Key Release /Basel, June 25, 2020 – Novartis has reached settlements with the US Department of Justice (DOJ) and the US Securities and Exchange Commission (SEC) resolving all Foreign Corrupt Practices Act (FCPA)…
- Media Release /The Novartis Innovation Prize: Assistive Tech for Multiple Sclerosis (MS) was initiated in 2019 as part of a commitment to innovation in Neuroscience to identify and encourage technology ideas from…
- Media Release /83% of technology (tech) professionals would consider working in healthcare and pharma, with 72% more likely to consider it compared to six months ago 86% of tech professionals agree: the…
- Media Release /Study discontinued due to feasibility of recruitment; no safety issues have been reported or efficacy conclusions made Novartis remains committed to ongoing research and development for COVID-19…
- Media Library /
- Biography /
- Featured News /
Novartis poised to expand impact on human health as it begins next era.
Pagination
- ‹ Previous page
- 1
- …
- 197
- 198
- 199
- 200
- 201
- 202
- 203
- …
- 264
- › Next page